Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Products under Development by Stage of Development | 7 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Products under Development by Therapy Area | 8 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Products under Development by Indication | 9 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Products under Development by Companies | 12 | 2 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Therapeutics Assessment | 14 | 7 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 2 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Companies Involved in Therapeutics Development | 21 | 5 |
| AbbVie Inc | 21 | 1 |
| Alkermes Plc | 22 | 1 |
| APT Therapeutics, Inc. | 23 | 1 |
| Mabtech Limited | 24 | 1 |
| Philogen S.p.A. | 25 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Drug Profiles | 26 | 14 |
| ALKS-4230 Drug Profile | 26 | 1 |
| APT-602 Drug Profile | 27 | 1 |
| basiliximab Drug Profile | 28 | 1 |
| basiliximab biobetter Drug Profile | 29 | 1 |
| daclizumab Drug Profile | 30 | 7 |
| Darleukin Drug Profile | 37 | 2 |
| Recombinant Protein to Agonize IL2RA, IL2RB and IL2RG for Autoimmune Diseases Drug Profile | 39 | 1 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Dormant Projects | 40 | 2 |
| Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Featured News &Press Releases | 42 | 17 |
| Sep 15, 2016: New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile | 42 | 2 |
| Sep 08, 2016: Biogen Demonstrates Data on ZINBRYTA at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis | 44 | 1 |
| Aug 15, 2016: Diplomat to Dispense ZINBRYTA for the Treatment of Multiple Sclerosis | 45 | 1 |
| Jul 05, 2016: Biogen and AbbVie s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis | 45 | 2 |
| May 27, 2016: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosi | 47 | 1 |
| May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 | 48 | 1 |
| Apr 29, 2016: Biogen and Abbvie Receive Positive Opinion From The CHMP on ZINBRYTA (daclizumab) For Treatment Of Multiple Sclerosis | 49 | 1 |
| Apr 22, 2016: Daclizumab Demonstrates Significant, Sustained Improvements In Cognition Compared To Interferon Beta-1A IM | 50 | 1 |
| Apr 20, 2016: Data Presented at AAN Highlight Impact of ZINBRYTA (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action | 51 | 2 |
| Apr 12, 2016: Biogen to Present Data on ZINBRYTA at 2016 AAN Annual Meeting | 53 | 1 |
| Jan 21, 2016: Philogen Announces Commencement of Phase III Pivotal Trial in Melanoma | 53 | 1 |
| Oct 20, 2015: Results Published from a Phase 3 Trial of Daclizumab High-Yield Process (DAC HYP) in Relapsing MS | 54 | 1 |
| Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS | 55 | 3 |
| Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress | 58 | 1 |
| Apr 29, 2015: FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |
